Literature DB >> 12653976

Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice.

Heidi M B Lesscher1, Alexis Bailey, J Peter H Burbach, Jan M Van Ree, Ian Kitchen, Mirjam A F M Gerrits.   

Abstract

Chronic treatment with the opioid antagonist naltrexone induces functional supersensitivity to opioid agonists, which may be explained by receptor up-regulation induced by opioid receptor blockade. In the present study, the levels of opioid receptor subtypes through the brain of mice were determined after chronic naltrexone treatment using quantitative in vitro autoradiography. This is the first complete mapping study in mice for micro-, delta- and kappa-opioid receptors after chronic naltrexone exposure. Treatment with naltrexone clearly induced up-regulation of micro- (mean 80%) and, to a lesser extent, delta-opioid receptors (mean 39%). The up-regulation of micro- and delta-opioid receptors was evident throughout the brain, although there was variation in the percentage change across brain regions. In contrast, consistent up-regulation of kappa-opioid receptors was observed in cortical structures only and was not so marked as for micro- and delta-opioid receptors. In noncortical regions kappa-opioid receptor expression was unchanged. Taken together, the present findings suggest opioid receptor subtype-selective regulation by chronic naltrexone treatment in mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653976     DOI: 10.1046/j.1460-9568.2003.02502.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  22 in total

1.  Behavioural activation system sensitivity is associated with cerebral μ-opioid receptor availability.

Authors:  Tomi Karjalainen; Lauri Tuominen; Sandra Manninen; Kari K Kalliokoski; Pirjo Nuutila; Iiro P Jääskeläinen; Riitta Hari; Mikko Sams; Lauri Nummenmaa
Journal:  Soc Cogn Affect Neurosci       Date:  2016-04-06       Impact factor: 3.436

Review 2.  Opioid Use Disorders: Perioperative Management of a Special Population.

Authors:  Emine Nalan Ward; Aurora Naa-Afoley Quaye; Timothy E Wilens
Journal:  Anesth Analg       Date:  2018-08       Impact factor: 5.108

3.  Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Authors:  Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman
Journal:  Mol Neurobiol       Date:  2011-09-24       Impact factor: 5.590

4.  Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone.

Authors:  Chi-Tso Chiu; Tangeng Ma; Ing K Ho
Journal:  Brain Res Bull       Date:  2005-09-30       Impact factor: 4.077

5.  Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.

Authors:  Farhana Sakloth; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2018-03-12       Impact factor: 3.157

Review 6.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

7.  Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A.

Authors:  Irma Onoprishvili; Eric J Simon
Journal:  Brain Res       Date:  2007-08-16       Impact factor: 3.252

8.  Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.

Authors:  Gianfranco Balboni; Stella Fiorini; Anna Baldisserotto; Claudio Trapella; Yusuke Sasaki; Akihiro Ambo; Ewa D Marczak; Lawrence H Lazarus; Severo Salvadori
Journal:  J Med Chem       Date:  2008-08-05       Impact factor: 7.446

9.  Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.

Authors:  Albert J Arias; Stephen Armeli; Joel Gelernter; Jonathan Covault; Antero Kallio; Sakari Karhuvaara; Tiina Koivisto; Rauno Mäkelä; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

Review 10.  Pharmacological traits of delta opioid receptors: pitfalls or opportunities?

Authors:  Richard M van Rijn; Julia N Defriel; Jennifer L Whistler
Journal:  Psychopharmacology (Berl)       Date:  2013-05-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.